# Masitinib in Patients With Mild Alzheimer's Disease

> **NCT05564169** · PHASE3 · NOT_YET_RECRUITING · sponsor: **AB Science** · enrollment: 600 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** Masitinib (4.5)
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT05564169
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05564169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05564169, "Masitinib in Patients With Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05564169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*